Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study
Max S. Topp(Universitätsklinikum Würzburg), Jennifer L. Crombie(Dana-Farber Cancer Institute), Susan O’Brien(University of California, Irvine), Jon Arnason(Beth Israel Deaconess Medical Center), Srikanth Ambati(Regeneron (United States)), John N. Allan(Cornell University), Jeffrey A. Barnes(Harvard University), Hesham Mohamed(Bristol-Myers Squibb (United States)), Matthew J. Matasar(Rutgers, The State University of New Jersey), Stephen M. Ansell(Mayo Clinic), Uri Abadi(Tel Aviv University), Neta Goldschmidt(National Institutes of Health), Jean‐Marie Michot(Institut Gustave Roussy), Min Zhu(Eye & ENT Hospital of Fudan University), Yuan Cheng(Taian City Central Hospital), I. Avivi(Tel Aviv University), Jurriaan Brouwer‐Visser(Montefiore Medical Center), Aafia Chaudhry(Regeneron (United States)), Dina M. Flink(Progenics Pharmaceuticals (United States))
Cited by 28
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k